Use of high-dose ganciclovir for a resistant cytomegalovirus infection due to UL97 mutation

P. West, M. Schmiedeskamp, H. Neeley, J. Oberholzer, E. Benedetti, B. Kaplan

    Research output: Contribution to journalArticlepeer-review

    22 Scopus citations

    Abstract

    Cytomegalovirus (CMV) infection is a major complication following solid organ transplantation resulting in significant morbidity and mortality. The guidelines published in 2004 have recommendations for therapy; however, the frequency of resistant CMV infection is increasing and therapy is not clearly defined. There are a few alternatives to ganciclovir such as foscarnet, cidofovir, and leflunomide; however, their use is limited by adverse effects. This report summarizes the successful use of high-dose ganciclovir for the treatment of a resistant CMV caused by UL97 mutation.

    Original languageEnglish (US)
    Pages (from-to)129-132
    Number of pages4
    JournalTransplant Infectious Disease
    Volume10
    Issue number2
    DOIs
    StatePublished - Apr 1 2008

    Keywords

    • Cytomegalovirus
    • Ganciclovir
    • Resistance
    • Transplant
    • UL97 mutation

    ASJC Scopus subject areas

    • Infectious Diseases
    • Transplantation

    Fingerprint Dive into the research topics of 'Use of high-dose ganciclovir for a resistant cytomegalovirus infection due to UL97 mutation'. Together they form a unique fingerprint.

    Cite this